GSTP1 (3F2) Mouse mAb (BSA and Azide Free) #10130
- WB
- IHC
- IF
Supporting Data
| REACTIVITY | H Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 23 |
| Source/Isotype | Mouse IgG1 |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- Mk-Monkey
Product Information
Product Usage Information
This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us. Optimal dilutions/concentrations should be determined by the end user.
Formulation
Storage
Specificity / Sensitivity
GSTP1 (3F2) Mouse mAb (BSA and Azide Free) detects endogenous levels of total GSTP1 protein. The antibody does not cross react with GST-tagged proteins.
Species Reactivity:
Human, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant GSTP1 protein.
Background
Glutathione S-transferases (GSTs) are a family of isoenzymes that detoxify electrophiles through conjugation to thiol-reduced glutathione (GSH). Thus, they are critical in protecting cells from toxins (drugs, pesticides, carcinogens) and oxidative stress (1). Eight isoforms of cytosolic-soluble GSTs (α, κ, μ, π, σ, θ, ζ, and ω) are identified, while only GST-α, -μ, and -π are described in the central nervous system (2). GSTP1 (GSTπ) is overexpressed in early stages of carcinogenesis and can be used as a neoplastic marker in tumor tissues (3). GSTP1 directly inhibits TRAF2 and JNK but not NF-κB (4,5). Corresponding GSTP1 gene polymorphisms affect substrate selectivity and stability, and the oxidative milieu in dopaminergic neurons, which increases the susceptibility to Parkinson’s disease (6).
- Hayes, J.D. et al. (2005) Annu Rev Pharmacol Toxicol 45, 51-88.
- Mannervik, B. et al. (2005) Methods Enzymol 401, 1-8.
- Ali-Osman, F. et al. (1997) Clin Cancer Res 3, 2253-61.
- Elsby, R. et al. (2003) J Biol Chem 278, 22243-9.
- Wu, Y. et al. (2006) Oncogene 25, 5787-800.
- Castro-Caldas, M. et al. (2009) J Mol Neurosci 38, 114-27.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.